Compare RBA & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBA | VTRS |
|---|---|---|
| Founded | 1958 | 1961 |
| Country | United States | United States |
| Employees | 8000 | 30000 |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 17.2B |
| IPO Year | N/A | 2019 |
| Metric | RBA | VTRS |
|---|---|---|
| Price | $104.47 | $14.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $122.20 | $13.50 |
| AVG Volume (30 Days) | 994.8K | ★ 7.0M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | 1.20% | ★ 3.43% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,299,900,000.00 |
| Revenue This Year | $4.43 | $4.41 |
| Revenue Next Year | $6.65 | $1.96 |
| P/E Ratio | $52.68 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $93.58 | $7.47 |
| 52 Week High | $119.58 | $16.47 |
| Indicator | RBA | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 61.55 | 64.77 |
| Support Level | $102.51 | $12.90 |
| Resistance Level | $106.01 | $16.38 |
| Average True Range (ATR) | 2.20 | 0.34 |
| MACD | 1.02 | 0.16 |
| Stochastic Oscillator | 91.50 | 97.06 |
RB Global has evolved into a leading global marketplace that connects buyers and sellers of commercial assets and vehicles. It is the result of the 2023 combination of Ritchie Bros. and IAA. Ritchie Bros.' roots were as an auctioneer facilitating transactions of commercial, construction, and transportation equipment (excavators, bulldozers, forklifts, and commercial trucks and trailers). However, it has evolved into an omnichannel marketplace. IAA has similar roots, though primarily focused on the salvage auction segment for consumer automobiles. The group provides ancillary services including title processing, transportation/towing, financing, data and appraisal, and so on. Its activities are international, though skewing approximately two-thirds to North America.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.